Related Experiment Video
Updated: May 2, 2026
06:30
Complete and Partial Resuscitative Endovascular Balloon Occlusion of the Aorta for Hemorrhagic Shock
Published on: May 19, 2022
10.5K
Autonomous device for application in late-phase hemorrhagic shock prevention
Vlad Oncescu1, Seoho Lee1, Abdurrahman Gumus2
1Sibley School of Mechanical and Aerospace Engineering, Cornell University, Ithaca, New York, United States of America.
Plos One
|March 4, 2014
Summary
A novel self-powered implantable device, hemoAID, autonomously monitors and treats hemorrhagic shock (HS) by releasing vasopressin when levels drop. This innovation offers a promising autonomous solution for HS prevention and management.
Area of Science:
- Biomedical Engineering
- Medical Devices
- Endocrinology
Background:
- Hemorrhagic shock (HS) is a primary cause of mortality in traumatic injuries.
- Changes in plasma vasopressin levels are observed during HS.
- Vasopressin administration may stabilize HS, suggesting a need for targeted delivery systems.
Purpose of the Study:
- To develop a self-powered, autonomous implantable device for continuous monitoring and treatment of HS.
- To automatically release vasopressin when levels fall below a critical threshold.
- To create an integrated system for proactive HS management.
Main Methods:
- Design and fabrication of a self-powered autonomous integrated device (hemoAID).
- Continuous monitoring of vasopressin levels within the device.
- Automated vasopressin release triggered by low vasopressin concentration.
- In vitro testing using sheep serum to validate device functionality at physiological concentrations.
Main Results:
- The hemoAID device successfully operated at physiological vasopressin concentrations.
- Demonstrated continuous monitoring and automated vasopressin release capabilities.
- Validated performance in a relevant biological matrix (sheep serum).
Conclusions:
- The hemoAID device represents a significant advancement in autonomous HS management.
- This technology paves the way for implantable devices for HS prevention.
- Autonomous vasopressin delivery holds potential for improving outcomes in traumatic injury patients.
